The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

By H. Ghebeh, S. Mohammed, Abeer Al-Omair, A. Qattan, C. Lehé, Ghofran Al-Qudaihi, N. Elkum, M. Alshabanah, Suad M Bin Amer, A. Tulbah and 3 more. Neoplasia, 2006

604 citations recorded by the source corpus.

B7-H1 molecule increases the apoptosis of tumor-reactive T lymphocytes and reduces their immunogenicity. Breast cancer is the second most common cause of mortality after lung cancer. Direct evidence linking B7-H1 with cancer has been shown in several malignancies; however, its expression in breast cancer has not been investigated. We used immunohistochemistry to investigate the expression of the B7-H1 molecule in 44 breast cancer specimens and to study its correlation with patients' clinicopathological parameters. The expression of B7-H1 was shown in 22 of 44 patients and was not restricted to the tumor epithelium (15 of 44, 34% in tumor cells), but was also expressed by tumor-infiltrating lymphocytes (TIL; 18 of 44, 41%). Interestingly, intratumor expression of B7-H1 was significantly associated with histologic grade III-negative (P = .012), estrogen receptor-negative (P = .036), and progesterone receptor-negative (P = .040) patients. In addition, the expression of B7-H1 in TIL was associated with large tumor size (P = .042), histologic grade III (P = .015), positivity of Her2/neu status (P = .019), and severe tumor lymphocyte infiltration (P = .001). Taken together, these data suggest that B7-H1 may be an important risk factor in breast cancer patients and may represent a potential immunotherapeutic target using monoclonal antibody against the B7-H1 molecule.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/22a0c69890bd6f8cbded425a823b01433320961b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. D. Pardoll
2. Lieping Chen
3. S. Topalian
4. Janis Taube
5. W. Zou
6. J. Wolchok
7. Antoni Ribas
8. James P. Allison

In Oncology

1. D. Pardoll
2. Lieping Chen
3. S. Topalian
4. Janis Taube
5. A. Klein
6. W. Zou
7. J. Wolchok
8. Antoni Ribas

Citations in the corpus

• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (2012, background): “Additionally, expression of B7-H1 by TILs has been reported to correlate with decreased patient survival (27, 28), suggesting that B7-H1 expression in the tumor microenvironment may exert an immunosuppressive function.”
• Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. (2014, neutral): “ciated with poor outcomes following chemoradiotherapy in cancer patients (27, 28).”
• Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. (2016, background): “Subsequent studies reported that PD-L1 is expressed in approximately 20% to 30% of TNBC,(20,35) is associated with infiltrating lymphocytes,(23) and correlates with higher histologic grade.(20,35) Mutations or deletions in the PTEN/PI3K pathway have been implicated in breast cancer(34,36); loss of P”
• PD-1 and PD-1 ligands: from discovery to clinical application. (2007, neutral): “SCCHN PD-L1 ND IHC(f) (98) Lung PD-L1 No IHC(f) (104) Renal cell PD-L1 Yes IHC(f, p) (105, 106) Esophagus PD-L1, PD-L2 Yes (L1 and L2) RT‐PCR (107) Stomach PD-L1 Yes IHC(p) (108) Breast PD-L1 ND IHC(f) ( 109 ) Oral squamous cell PD-L1 ND IHC(f) (110) Urothelial cell PD-L1 Yes IHC(f) (111) Ovary PD-L”